{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Disability Rating Scale as a Predictor of Long-term Outcome in Severe Traumatic Brain Injury"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised to receive erythropoietin or placebo"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria encompassed adults with severe TBI, and the study was conducted across multiple trauma centers."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive erythropoietin or placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the Disability Rating Scale (DRS) as a predictor of favorable 6-month Glasgow Outcome Scale extended (GOS-E)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "DRS was recorded weekly from weeks 1 to 4 post-injury, and GOS-E was evaluated at 6 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was maintained for outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 200 participants were randomised, with 100 assigned to each group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "An intention-to-treat analysis was performed."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The model using baseline demographic and injury severity variables with week 1 DRS achieved an area under the receiver operating characteristic curve of 0.82, which increased to 0.88 when including weekly DRS until week 4."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported in either group, with mild side effects occurring in 3% of the intervention group and 1% of the control group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}